1. Home
  2. SEVN vs PYXS Comparison

SEVN vs PYXS Comparison

Compare SEVN & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seven Hills Realty Trust

SEVN

Seven Hills Realty Trust

HOLD

Current Price

$7.41

Market Cap

174.0M

Sector

Real Estate

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$3.21

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEVN
PYXS
Founded
1986
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.0M
141.3M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
SEVN
PYXS
Price
$7.41
$3.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$10.50
$7.00
AVG Volume (30 Days)
114.4K
933.1K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
13.90%
N/A
EPS Growth
N/A
3.03
EPS
0.19
N/A
Revenue
$29,383,000.00
$13,858,000.00
Revenue This Year
$27.75
N/A
Revenue Next Year
$4.06
$7,043.98
P/E Ratio
$38.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.37
$1.03
52 Week High
$11.15
$5.55

Technical Indicators

Market Signals
Indicator
SEVN
PYXS
Relative Strength Index (RSI) 34.32 49.54
Support Level N/A $1.37
Resistance Level $7.84 $3.45
Average True Range (ATR) 0.12 0.33
MACD -0.01 -0.01
Stochastic Oscillator 9.82 31.32

Price Performance

Historical Comparison
SEVN
PYXS

About SEVN Seven Hills Realty Trust

Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: